United Therapeutics Corporation Presents New Data from TETON-1, Advance Outcomes, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis

Published: 2026-05-11 14:06:40 ET UTHR

Published on 05/11/2026 at 02:06 pm EDT

United Therapeutics Corporation announced that 12 new data presentations across its commercial and development portfolio will be presented at the American Thoracic Society International Conference, May 15-20, in Orlando. Presentations of results from the positive TETON phase 3 pivotal studies of inhaled treprostinil in idiopathic pulmonary fibrosis (IPF) include efficacy and safety results from TETON-1 and integrated results from TETON-1 and TETON-2. Results from the successful ADVANCE OUTCOMES study of ralinepag in pulmonary arterial hypertension (PAH) will be presented. Additional presentations include an interim analysis from the TETON-PPF study of inhaled treprostinil in progressive pulmonary fibrosis (PPF), preliminary results from the PHINDER study of patients with interstitial lung disease (ILD) with and without pulmonary hypertension (PH), and interim results from the ARTISAN study of parenteral treprostinil in PAH.

Poster Presentations Include: ARTISAN Interim Analysis: Early Treatment with High-Dose Treprostinil Reduces Mean Pulmonary Artery Pressure and Improves Risk Status in Pulmonary Arterial Hypertension, Patient Insights into Subcutaneous Pump Therapy in Pulmonary Arterial Hypertension, Accuracy of Clinician Suspicion for Pulmonary Hypertension in Interstitial Lung Disease by Care Setting: Interim Comparison from the PHINDER Study, Real-world Dosing of Parenteral Treprostinil Post-Sotatercept Launch, Real-World Persistence to Oral Treprostinil in Patients with Pulmonary Arterial Hypertension: A Decade in Review, TETON Phase 3 Clinical Trials of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis: Integrated Efficacy and Safety Results for TETON-1 and TETON-2, Clinical Outcomes with Parenteral Induction Therapy in Patients with Methamphetamine-Associated PAH: A Subgroup Analysis of the EXPEDITE Study, Patient Reported Outcomes in Interstitial Lung Disease with and without Pulmonary Hypertension: Interim Results from the PHINDER Study, TETON-1 Phase 3 Clinical Trial of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis, TETON-PPF Clinical Trial of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis, ADVANCE OUTCOMES: A Phase 3, Double-Blind, Placebo-Controlled Clinical Trial of Ralinepag for the Treatment of Pulmonary Arterial Hypertension, Real-World Comparison of Antifibrotic-Treated and Untreated Patients with Idiopathic Pulmonary Fibrosis in a Commercial and Medicare Advantage Population.